pi3k-in-10

PI3K-IN-10 is a potent inhibitor of pan-PI3K (Phosphoinositide 3-kinase).

AOD9604 acetate(221231-10-3 free base) is a potential anti-obesity peptide based on the human growth hormone.

Cathepsin K Inhibitor 3, exhibiting an IC50 value of 0.5 nM, is a highly selective inhibitor of cathepsin K, featuring a favorable pharmacokinetic profile. It holds potential for use in studies of osteoarthritis (OA).

K-Ras ligand-Linker Conjugate 3 (Compound 001371) is a chemical compound comprising a ligand for the K-Ras recruiting moiety and a PROTAC linker, responsible for recruiting E3 ligases (e.g., VHL, CRBN, MDM2, and IAP). This compound is essential for synthesizing PROTAC K-Ras Degrader-1, a potent degrader with a degradation efficacy of ≥70% in SW1573 cells[1].

20)abeotaxa-4(20),11-dien-10-one'>2alpha,7beta,13alpha-Triacetoxy-5alpha-cinnamoyloxy-9beta-hydroxy-2(3->20)abeotaxa-4(20),11-dien-10-one is a natural product for research related to life sciences. The catalog number is TN2840 and the CAS number is 322471-42-1.

3,4-Seco-3-oxobisabol-10-ene-4,1-olide is a natural product for research related to life sciences. The catalog number is TN5372 and the CAS number is 1564265-85-5.

TNF-α (10-36), human (TFA) is a peptide of human TNF-α.

Heterocyclic compounds as covalent inhibitors of G12C mutant K-Ras protein useful for treating cancers.K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

8,9-Epoxy-3-isobutyryloxy-10-(2-methylbutanoyl)thymol, a chemical component of essential oils from Telekia speciosa, exhibits significant antiproliferative activity against human cancer cell lines in vitro.

PI3Kδ-IN-10 is a highly potent and orally active PI3Kδ inhibitor (IC50 = 2 nM) that robustly suppresses the downstream AKT pathway to induce subsequent apoptosis in hepatocellular carcinoma models.

K 259-3, a methyl ester of K 259-2, is an inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase.

3-(2'-Deoxyribofuranosyl)pyrimido(1,2-a)purin-10(3H)-one is a malondialdehyde-deoxyguanosine adduct.

Lup-20(29)-en-28-oic acid, 3-hydroxy-, 10-carboxydecyl ester, (3beta)- is a bioactive chemical.

PI3K/mTOR Inhibitor-7 is a potent dual PI3K/mTOR inhibitor. PI3K/mTOR Inhibitor-7 is 4.7-fold more potent than gedatolisib, with IC50 values of 1.4 μM and 0.3 μM, respectively. 10 μM of PI3K/mTOR Inhibitor-7 is able to significantly inhibit the PI3K/Akt/mTOR signalling pathway. PI3K/mTOR Inhibitor-7 has shown potential for research in cancer diseases.

The Immuno-Oncology Screening Library consists of 2 plates and contains more than 90 cancer and immunology-associated compounds in a 96-well Matrix tube rack format as 10 mM stock solutions in DMSO. This library includes a variety of immuno-oncology target modulators, including but not limited to, adenosine, CCR, CXCR, and TLR agonists and antagonists, BTK, PI3K, VEGFR, and BRAF inhibitors, PD-1/PDL-1 interaction inhibitors, and HDAC inhibitors. Please review the product insert for a full list of targets. Stability data is not available for the compounds as supplied in the screening library.

PF-06843195 is a selective PI3Kα inhibitor, demonstrating potent activity with an IC50 of 18 nM in Rat1 fibroblasts and Kis for PI3Kα and PI3Kδ less than 0.018 nM and 0.28 nM, respectively, in biochemical kinase assays. It effectively suppresses the PI3K mTOR signaling pathway and exhibits durable antitumor efficacy[1].

PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET. It impedes RET function, promoting autophagic breakdown of FLT3, and suppresses the PI3K and Ras/ERK pathways, contributing to its anti-leukemic effects. The compound's antitumor efficacy is demonstrated in both a mouse MV4-11 flank xenograft model (doses of 3 and 10 mg/kg; po) and an allogeneic xenograft mouse model (dose of 40 mg/kg; po) [1].

PI3K-IN-23 is a (E)-9-oxooctadec-10-en-12-ynoic acid analogue that promotes glucose uptake (EC50: 7.00 μM).

PI3K mTOR Inhibitor-6 (Compound 19c) is a potent dual PI3K mTOR inhibitor, exhibiting greater stability than gedatolisib in artificial gastric fluid. At 10 μM, PI3K mTOR Inhibitor-6 significantly inhibits the PI3K Akt mTOR signaling pathway and has shown potential for cancer research.

AKT-IN-10 is a potent AKT inhibitor with research potential in breast and prostate cancers. It targets protein kinase B (PKB, also known as AKT), a key component of the PI3K AKT mTOR signaling pathway that is crucial for cell growth, survival, differentiation, and metabolism.

Compound F27 (Antileishmanial agent-19) is an antileishmanial compound effective against L. donovani promastigotes, demonstrating an IC50 of 3.39 μM. It functions by inhibiting the Leishmania prolyl-tRNA synthetase and disrupting the host PI3K/Akt/CREB axis-mediated IL-10 secretion. Additionally, Compound F27 promotes autophagy-mediated apoptosis in L. donovani promastigotes and has been shown to reduce parasite burden in L.d-infected animals [1].